The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)
Abstract
A three-arm Phase III trial was started in November 2012. Preoperative chemotherapy with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced esophageal cancer in Japan, while preoperative chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries. Preoperative chemotherapy with docetaxel, cisplatin plus 5-fluorouracil is another promising regimen. The purpose of this study is to confirm the superiority of docetaxel, cisplatin plus 5-fluorouracil over cisplatin plus 5-fluorouracil and the superiority of cisplatin plus 5-fluorouracil with chemoradiotherapy over cisplatin plus 5-fluorouracil as preoperative therapy for squamous cell carcinoma of esophagus. A total of 501 patients will be accrued from 41 Japanese institutions within 6.25 years. The primary endpoint is overall survival and the secondary endpoints include progression-free survival, %R0 resection, response rate, pathologic complete response rate and adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Ando, N., Kato, H., Igaki, H., Shinoda, M., Ozawa, S., Shimizu, H., Nakamura, T., Yabusaki, H., Aoyama, N., Kurita, A., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2049-9 · Cited by 1,427
Self-citationGebski, V., Burmeister, B., Smithers, B. M., Foo, K., Zalcberg, J., & Simes, J. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70039-6 · Cited by 1,158
Ando, N., Iizuka, T., Ide, H., Ishida, K., Shinoda, M., Nishimaki, T., Takiyama, W., Watanabe, H., Isono, K., Aoyama, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.095 · Cited by 722
Self-citationSchoenfeld, D. A., & Richter, J. R. (1982) · Biometrics · doi:10.2307/2530299 · Cited by 354
Progress in multidisciplinary treatment for esophageal cancer in Japan as reflected in JCOG studies
Ando, N. (2011) · Esophagus · doi:10.1007/s10388-011-0282-8 · Cited by 12
Self-citationNakamura, K., Shibata, T., Takashima, A., Yamamoto, S., & Fukuda, H. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys122 · Cited by 9
Self-citation
Cited by
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro, J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03614 · Cited by 795
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0642-8 · Cited by 569
Self-citationRecent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
Ohashi, S., Miyamoto, S., Kikuchi, O., Goto, T., Amanuma, Y., & Muto, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.054 · Cited by 530
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0641-9 · Cited by 519
Self-citation
Metadata
- Authors
- Nakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., Fukuda, H., Kitagawa, Y., & on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group
- Venue
- Japanese Journal of Clinical Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-26
- Volume
- 43
- Issue
- 7
- Pages
- 752-755
- ISSN
- 0368-2811 (ISSN-L)
- 1465-3621
- OpenAlex
- W2123279461
- Cited by
- 289
- References
- 7
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). https://app.cochat.ai/papers/10.1093/jjco/hyt061
- The paper
- Nakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., Fukuda, H., Kitagawa, Y., & on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group. (2013). Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyt061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.